A5047483299- Prostate Cancer Treatment and Research
- Advanced Radiotherapy Techniques
- Prostate Cancer Diagnosis and Treatment
- Management of metastatic bone disease
- Metabolism, Diabetes, and Cancer
- Colorectal Cancer Treatments and Studies
- Endometrial and Cervical Cancer Treatments
- Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Advances in Oncology and Radiotherapy
- Cancer Risks and Factors
- Radiation Therapy and Dosimetry
- Hormonal and reproductive studies
- Radiation Dose and Imaging
- Renal cell carcinoma treatment
- Lung Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cancer Treatment and Pharmacology
- Multiple and Secondary Primary Cancers
- Health Systems, Economic Evaluations, Quality of Life
- Cervical Cancer and HPV Research
- Bone health and treatments
- Renal and related cancers
- Ovarian cancer diagnosis and treatment
- Colorectal Cancer Screening and Detection
CancerCare Manitoba
2013-2024
University of Manitoba
2010-2021
325 Background: We aim to report the long-term efficacy outcomes of PATRIOT trial, a multicenter phase 2 randomised trial every-other-day (EOD) versus once-a-week (QW) schedule for stereotactic body radiotherapy (SBRT) prostate cancer (NCT01423474). Methods: Between January 2012 and November 2013, 152 men with low intermediate risk were SBRT 40Gy in 5 fractions, delivered EOD (n=75) or QW (n=77). The oncological evaluated biochemical failure (BF) (based on Phoenix criteria), metastases free...
Patient-specific assessment, disease monitoring, and the development of an accurate early surrogate therapeutic efficacy locally advanced prostate cancer still remain a clinical challenge. Contrary to biopsies, circulating tumor cell (CTC) collection from blood is less-invasive method has potential as real-time liquid biopsy marker for treatment efficacy. In this study, we used size-based filtration isolate CTCs 100 patients with high-risk localized disease. five time points: +0, +2, +6, +12...
Abstract Androgen deprivation therapy (ADT) used for prostate cancer (PCa) management is associated with metabolic and anthropometric toxicity. Metformin given concurrent to ADT hypothesized counteract these changes. This planned interim analysis reports the gastrointestinal genitourinary toxicity profiles of PCa patients receiving prostate/pelvic radiotherapy plus metformin versus placebo as part a phase 2 randomized controlled trial. Men intermediate or high-risk were 1:1 placebo. Both...
6 Background: Stereotactic body radiotherapy (SBRT) for the treatment of prostate cancer is rapidly increasing. Reported regimens differ in time, dose, and fractionation. We report results a multicentre, Canadian randomized phase II study to investigate impact overall time on quality life (QOL) toxicity. Methods: Men with cT1-2b, Gleason <=7, PSA <= 20 ng/mL were randomly assigned 40 Gy 5 fractions delivered every other day (11 days) vs. once per week (29 using gantry-based SBRT. QOL...
Background: Despite level 1 evidence demonstrating the equivalence of single-fraction radiotherapy (SFRT) and multiple-fraction (MFRT) for palliation painful bone metastases, SFRT remains underused. In 2015, to encourage sustainable use palliative radiation oncology resources, CancerCare Manitoba disseminated, each oncologist in Manitoba, guidelines from Choosing Wisely Canada (CWC) that recommend SFRT. We assessed whether dissemination influenced 2016, we identified factors associated with...
Context Daily variations in bladder size and position can negatively impact the ability to accurately deliver radiation. Aims We attempted quantify how volumes positions change over course of radiotherapy for muscle invasive cancer planning target volume (PTV) margins required account such changes. Methods material Cone-beam computed tomography (CT) images 28 patients during their first, second, third fractions weekly thereafter were acquired. Bladders contoured volume, centre mass, maximal...
Objectives: Androgen deprivation therapy (ADT) is the standard of care for men with nonmetastatic hormone-sensitive prostate cancer (nmHSPC) after treatment failure. Although intermittent ADT (iADT) noninferior to continuous outcomes, superior quality life and cost-to-benefit ratio, little known regarding its real-world utilization. The authors aimed determine utilization iADT in a Canadian Provincial Cancer Program relapsed nmHSPC identified risk factors associated nonreceipt iADT....
Results:The study population consisted of 206 patients treated with surgery and 136 RT.Median follow up was 6.6 years.Patients in the surgical cohort were younger, mean age: 48.9 versus 60.7 years, p < 0.001, had larger tumours, maximum dimension: 25.7 +/-10.3mm 20.3 +/-6.6 mm, 0.001.After all VS treatments, population's PFS 92.8 +/-1.5% at five years 83.7% +/-2.9% 10 years.The SH preservation last 34.2%.SAEs occurred 4.7% patients.In radiotherapy patients, 17% previous (four complete...